Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Beginning Cash Balance (2017 - 2020)

Northwest Biotherapeutics' Beginning Cash Balance history spans 8 years, with the latest figure at $315000.0 for Q4 2020.

  • Quarterly results put Beginning Cash Balance at $315000.0 for Q4 2020, changed N/A from a year ago — trailing twelve months through Dec 2020 was $379000.0 (up 15.2% YoY), and the annual figure for FY2020 was $379000.0, up 15.2%.
  • Beginning Cash Balance for Q4 2020 was $315000.0 at Northwest Biotherapeutics, up from $64000.0 in the prior quarter.
  • In the past five years, Beginning Cash Balance ranged from a high of $764000.0 in Q3 2017 to a low of $41000.0 in Q4 2018.
  • The 4-year median for Beginning Cash Balance is $322000.0 (2019), against an average of $352500.0.
  • Peak annual rise in Beginning Cash Balance hit 254.67% in 2018, while the deepest fall reached 88.29% in 2018.
  • Year by year, Beginning Cash Balance stood at $350000.0 in 2017, then plummeted by 88.29% to $41000.0 in 2018, then surged by 702.44% to $329000.0 in 2019, then dropped by 4.26% to $315000.0 in 2020.
  • According to Business Quant data, Beginning Cash Balance over the past three periods came in at $315000.0, $64000.0, and $329000.0 for Q4 2020, Q1 2020, and Q1 2019 respectively.